{"id":"https://openalex.org/W4361815360","doi":"https://doi.org/10.1158/1078-0432.22476794.v1","title":"Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia","display_name":"Supplementary Data from Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361815360","doi":"https://doi.org/10.1158/1078-0432.22476794.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22476794.v1","doi":"https://doi.org/10.1158/1078-0432.22476794.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22476794.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.22476794.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057933586","display_name":"Kendra Lynn Sweet","orcid":"https://orcid.org/0000-0001-6248-3317","observed_orcids":["https://orcid.org/0000-0001-6248-3317"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kendra Sweet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010075752","display_name":"Rami S. Komrokji","orcid":"https://orcid.org/0000-0002-1876-5269","observed_orcids":["https://orcid.org/0000-0002-1876-5269"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rami Komrokji","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041754278","display_name":"Eric Padron","orcid":"https://orcid.org/0000-0002-4707-7916","observed_orcids":["https://orcid.org/0000-0002-4707-7916"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Padron","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036862186","display_name":"Christopher L. Cubitt","orcid":"https://orcid.org/0000-0001-6343-7451","observed_orcids":["https://orcid.org/0000-0001-6343-7451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher L. Cubitt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033566009","display_name":"Joel G. Turner","orcid":"https://orcid.org/0009-0002-6081-3866","observed_orcids":["https://orcid.org/0009-0002-6081-3866","https://orcid.org/0000-0002-2358-6898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joel G. Turner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060582867","display_name":"Junmin Zhou","orcid":"https://orcid.org/0009-0007-4949-8742","observed_orcids":["https://orcid.org/0009-0007-4949-8742"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Junmin Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066001318","display_name":"Alan F. List","orcid":"https://orcid.org/0000-0002-1647-2972","observed_orcids":["https://orcid.org/0000-0002-1647-2972"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan F. List","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1647-2972","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029369362","display_name":"David Andrew Sallman","orcid":"https://orcid.org/0000-0003-0504-8233","observed_orcids":["https://orcid.org/0000-0003-0504-8233"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David A. Sallman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035721135","display_name":"Jana L. Dawson","orcid":"https://orcid.org/0000-0002-4901-0897","observed_orcids":["https://orcid.org/0000-0002-4901-0897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jana L. Dawson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4901-0897","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel M. Sullivan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084789778","display_name":"Julio C. Ch\u00e1vez","orcid":"https://orcid.org/0000-0002-2045-6238","observed_orcids":["https://orcid.org/0000-0002-2045-6238"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julio Chavez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025137989","display_name":"Bijal Dinesh Shah","orcid":"https://orcid.org/0000-0003-4328-6021","observed_orcids":["https://orcid.org/0000-0003-4328-6021"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bijal D. Shah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5041443589","display_name":"Jeffrey E. Lancet","orcid":"https://orcid.org/0000-0002-7751-7310","observed_orcids":["https://orcid.org/0000-0002-7751-7310"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey E. Lancet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.9980000257492065},{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.972000002861023},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/poor-risk-aml","display_name":"poor-risk AML","score":0.8059999942779541},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.6110000014305115},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.3490000069141388},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.48100000619888306}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.8424715995788574},{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.8359624743461609},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7938066124916077},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6361336708068848},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46442902088165283},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43553316593170166},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4350598454475403},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3759078085422516}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.22476794.v1","doi":"https://doi.org/10.1158/1078-0432.22476794.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22476794.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22476794","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Data_from_Phase_I_Clinical_Trial_of_Selinexor_in_Combination_with_Daunorubicin_and_Cytarabine_in_Previously_Untreated_Poor-Risk_Acute_Myeloid_Leukemia/22476794","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22476794.v1","doi":"https://doi.org/10.1158/1078-0432.22476794.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22476794.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.7099999785423279,"display_name":"No poverty","id":"https://metadata.un.org/sdg/1"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361815329","https://openalex.org/W2981488108","https://openalex.org/W2729664746","https://openalex.org/W2991237757","https://openalex.org/W2781793078","https://openalex.org/W7052049733","https://openalex.org/W4400802356","https://openalex.org/W4386407968","https://openalex.org/W2976970352","https://openalex.org/W2904547506"],"abstract_inverted_index":{"Supplementary":[0],"Methods.":[1]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-04-05T00:00:00"}